REGENXBIO Inc. (NASDAQ:RGNX) Receives $31.63 Average Price Target from Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $31.63.

A number of research analysts have recently weighed in on RGNX shares. Wall Street Zen upgraded REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. The Goldman Sachs Group dropped their price objective on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. HC Wainwright reduced their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Monday, March 17th. Chardan Capital reissued a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research report on Monday, June 9th. Finally, Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th.

REGENXBIO Stock Up 4.7%

REGENXBIO stock opened at $8.62 on Monday. The company has a market capitalization of $432.38 million, a PE ratio of -2.77 and a beta of 1.06. REGENXBIO has a 12-month low of $5.04 and a 12-month high of $15.36. The firm’s fifty day moving average is $9.01 and its 200 day moving average is $7.86.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative net margin of 100.62% and a negative return on equity of 53.29%. The firm had revenue of $89.01 million during the quarter, compared to the consensus estimate of $105.35 million. Sell-side analysts expect that REGENXBIO will post -4.84 EPS for the current fiscal year.

Insider Buying and Selling at REGENXBIO

In related news, Director Kenneth T. Mills sold 20,602 shares of REGENXBIO stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director owned 475,103 shares of the company’s stock, valued at approximately $3,758,064.73. The trade was a 4.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.79% of the stock is owned by corporate insiders.

Institutional Trading of REGENXBIO

A number of large investors have recently bought and sold shares of the company. FNY Investment Advisers LLC bought a new position in shares of REGENXBIO during the 1st quarter worth $35,000. Brooklyn Investment Group boosted its position in REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 3,466 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of REGENXBIO in the fourth quarter worth about $54,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of REGENXBIO in the fourth quarter worth about $79,000. Finally, Laurion Capital Management LP bought a new stake in shares of REGENXBIO in the fourth quarter valued at approximately $79,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.